Bone marrow necrosis associated with the use of imatinib mesylate in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Kosei
K
Matsue
Masami
M
Takeuchi
Mihoko
M
Koseki
Hidetaka
H
Uryu
D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001549:Benzamides; D001853:Bone Marrow / Q000473:pathology; D001855:Bone Marrow Diseases / Q000097:blood / Q000139:chemically induced* / Q000473:pathology*; D006801:Humans; D000068877:Imatinib Mesylate; D008297:Male; D009336:Necrosis / Q000139:chemically induced / Q000473:pathology; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000097:blood / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects*
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate